BioMarin Pharmaceutical - 22 Year Stock Price History | BMRN

Historical daily share price chart and data for BioMarin Pharmaceutical since 1999 adjusted for splits. The latest closing stock price for BioMarin Pharmaceutical as of October 27, 2021 is 71.72.
  • The all-time high BioMarin Pharmaceutical stock closing price was 149.13 on July 20, 2015.
  • The BioMarin Pharmaceutical 52-week high stock price is 92.56, which is 29.1% above the current share price.
  • The BioMarin Pharmaceutical 52-week low stock price is 71.59, which is 0.2% below the current share price.
  • The average BioMarin Pharmaceutical stock price for the last 52 weeks is 79.64.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
BioMarin Pharmaceutical Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 79.5495 86.3000 90.6900 71.7200 71.7200 -18.21%
2020 91.5134 84.0400 131.0300 71.3700 87.6900 3.71%
2019 82.5653 84.9600 98.6200 64.2700 84.5500 -0.70%
2018 92.1163 91.0300 106.0700 76.0100 85.1500 -4.51%
2017 88.8143 85.8400 98.8200 80.6000 89.1700 7.64%
2016 86.6998 104.9200 104.9200 64.7400 82.8400 -20.92%
2015 117.0456 92.1700 149.1300 90.2800 104.7600 15.88%
2014 70.7528 69.2700 94.1900 55.7800 90.4000 28.50%
2013 63.4324 51.9200 78.3880 51.5600 70.3500 42.99%
2012 39.1417 34.9300 50.1700 32.1300 49.2000 43.11%
2011 28.4184 26.6100 35.3800 23.4600 34.3800 27.66%
2010 22.1536 18.9500 28.2500 18.2400 26.9300 43.17%
2009 15.6685 17.6500 20.8300 10.1400 18.8100 5.67%
2008 29.7800 36.6400 40.3900 13.5900 17.8000 -49.72%
2007 21.0564 16.1000 36.5800 15.7100 35.4000 115.99%
2006 14.3090 10.9900 18.0400 10.9600 16.3900 52.04%
2005 7.3643 6.2600 11.4100 4.4300 10.7800 68.70%
2004 6.2104 7.9100 8.7900 3.8700 6.3900 -17.65%
2003 9.4406 7.0300 13.3200 6.4100 7.7600 10.07%
2002 7.2827 13.2400 13.9500 3.6500 7.0500 -47.54%
2001 11.0435 9.5000 14.1600 7.3130 13.4400 38.73%
2000 18.0555 12.7500 38.7500 7.1560 9.6880 -17.55%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $13.462B $1.860B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86